{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:09Z","timestamp":1776408669278,"version":"3.51.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HE23C002800"],"award-info":[{"award-number":["HE23C002800"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2023-00216446"],"award-info":[{"award-number":["RS-2023-00216446"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06849-w","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T01:28:57Z","timestamp":1774229337000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of bortezomib maintenance following VMP induction in transplant-ineligible multiple myeloma: a target trial emulation study"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9052-5912","authenticated-orcid":false,"given":"Jung Yeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5438-7819","authenticated-orcid":false,"given":"Suein","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8313-8800","authenticated-orcid":false,"given":"Seungpil","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-4136","authenticated-orcid":false,"given":"Sung-Soo","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-8436","authenticated-orcid":false,"given":"Jin Seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8472-7041","authenticated-orcid":false,"given":"Seung-Hwan","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-8200","authenticated-orcid":false,"given":"Young-Woo","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-3991","authenticated-orcid":false,"given":"Seung-Ah","family":"Yahng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4635-5697","authenticated-orcid":false,"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8784-6839","authenticated-orcid":false,"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1781-2262","authenticated-orcid":false,"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-2067","authenticated-orcid":false,"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0088-0995","authenticated-orcid":false,"given":"Min Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-7936","authenticated-orcid":false,"given":"Yundeok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8128-3310","authenticated-orcid":false,"given":"Jihyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1940-0392","authenticated-orcid":false,"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Korean Multiple Myeloma Working Party (KMMWP)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"6849_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364:1046\u20131060. https:\/\/doi.org\/10.1056\/NEJMra1011442","journal-title":"N Engl J Med"},{"key":"6849_CR2","volume-title":"SEER cancer statistics Review, 1975\u20132009 (Vintage 2009 Populations)","author":"N Howlader","year":"2012","unstructured":"Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF et al (2012) SEER cancer statistics Review, 1975\u20132009 (Vintage 2009 Populations). National Cancer Institute, Bethesda, MD"},{"key":"6849_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1200\/JCO.2013.52.0586","volume":"32","author":"A Palumbo","year":"2014","unstructured":"Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V et al (2014) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 32:634\u2013640. https:\/\/doi.org\/10.1200\/JCO.2013.52.0586","journal-title":"J Clin Oncol"},{"key":"6849_CR4","doi-asserted-by":"publisher","first-page":"1028571","DOI":"10.3389\/fonc.2023.1028571","volume":"13","author":"Z Zhuang","year":"2023","unstructured":"Zhuang Z, Tian Y, Shi L, Zou D, Feng R, Tian WW et al (2023) Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China. Front Oncol 13:1028571. https:\/\/doi.org\/10.3389\/fonc.2023.1028571","journal-title":"Front Oncol"},{"key":"6849_CR5","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1182\/blood-2012-05-427815","volume":"120","author":"MV Mateos","year":"2012","unstructured":"Mateos MV, Oriol A, Martinez-Lopez J, Gutierrez N, Teruel AI, Lopez de la Guia A et al (2012) Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 120:2581\u20132588. https:\/\/doi.org\/10.1182\/blood-2012-05-427815","journal-title":"Blood"},{"key":"6849_CR6","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/leu.2017.35","volume":"31","author":"L de la Rosi\u00f1ol","year":"2017","unstructured":"Rosi\u00f1ol L, Oriol A, Teruel AI, de la Gu\u00eda AL, Blanchard M, de la Rubia J et al (2017) Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial. Leukemia 31:1922\u20131927. https:\/\/doi.org\/10.1038\/leu.2017.35","journal-title":"Leukemia"},{"key":"6849_CR7","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L et al (2021) Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol 22:1378\u20131390. https:\/\/doi.org\/10.1016\/S1470-2045(21)00428-9","journal-title":"Lancet Oncol"},{"key":"6849_CR8","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O et al (2010) Bortezomib plus Melphalan and prednisone compared with Melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259\u20132266. https:\/\/doi.org\/10.1200\/JCO.2009.26.0638","journal-title":"J Clin Oncol"},{"key":"6849_CR9","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-12-35","volume":"12","author":"I Proskorovsky","year":"2014","unstructured":"Proskorovsky I, Lewis P, Williams CD, Jordan K, Kyriakou C, Ishak J et al (2014) Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health Qual Life Outcomes 12:35. https:\/\/doi.org\/10.1186\/1477-7525-12-35","journal-title":"Health Qual Life Outcomes"},{"key":"6849_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","volume":"22","author":"K Jordan","year":"2014","unstructured":"Jordan K, Proskorovsky I, Lewis P, Ishak J, Payne K, Lordan N et al (2014) Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Support Care Cancer 22:417\u2013426. https:\/\/doi.org\/10.1007\/s00520-013-1991-4","journal-title":"Support Care Cancer"},{"key":"6849_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41408-023-00849-8","volume":"13","author":"K Forde","year":"2023","unstructured":"Forde K, Cocks K, Wells JR, McMillan I, Kyriakou C, EORTC Quality of Life Group (2023) Use of the European organisation for research and treatment of cancer multiple myeloma module (EORTC QLQ-MY20): a review of the literature 25 years after development. Blood Cancer J 13:79. https:\/\/doi.org\/10.1038\/s41408-023-00849-8","journal-title":"Blood Cancer J"},{"key":"6849_CR12","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","volume":"43","author":"K Cocks","year":"2007","unstructured":"Cocks K, Cohen D, Wisloff F, Sezer O, Lee S, Hippe E et al (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43:1670\u20131678. https:\/\/doi.org\/10.1016\/j.ejca.2007.04.022","journal-title":"Eur J Cancer"},{"key":"6849_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3324\/haematol.2025.287889","volume":"111","author":"S LeeJY, Jung","year":"2026","unstructured":"Lee JY, Jung S, Choi S, Park SS, Kim JS, Lee JJ et al (2026) Efficacy, safety, and health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma patients receiving bortezomib maintenance therapy: a study of the Korean Multiple Myeloma Working Party KMMWP-174 study. Haematologica 111:379\u2013384. https:\/\/doi.org\/10.3324\/haematol.2025.287889","journal-title":"Haematologica"},{"key":"6849_CR14","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H et al (2012) Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol 30:2946\u20132955. https:\/\/doi.org\/10.1200\/JCO.2011.39.6820","journal-title":"J Clin Oncol"},{"key":"6849_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A et al (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395:132\u2013141. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3","journal-title":"Lancet"},{"key":"6849_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bjh.14532","volume":"177","author":"JG Berdeja","year":"2017","unstructured":"Berdeja JG, Bauer T, Arrowsmith E, Essell J, Murphy P, Reeves JA Jr et al (2017) Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Br J Haematol 177:254\u2013262. https:\/\/doi.org\/10.1111\/bjh.14532","journal-title":"Br J Haematol"},{"key":"6849_CR17","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412\u20133420. https:\/\/doi.org\/10.1200\/JCO.2005.04.242","journal-title":"J Clin Oncol"},{"key":"6849_CR18","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015) Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol 33:2863\u20132869. https:\/\/doi.org\/10.1200\/JCO.2015.61.2267","journal-title":"J Clin Oncol"},{"key":"6849_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461\u2013470. https:\/\/doi.org\/10.7326\/0003-4819-130-6-199903160-00002","journal-title":"Ann Intern Med"},{"key":"6849_CR20","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P et al (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328\u2013e346. https:\/\/doi.org\/10.1016\/S1470-2045(16)30206-6","journal-title":"Lancet Oncol"},{"key":"6849_CR21","volume-title":"Common terminology criteria for adverse events v4.03","author":"National Cancer Institute","year":"2009","unstructured":"National Cancer Institute (2009) Common terminology criteria for adverse events v4.03. National Cancer Institute, Bethesda, MD"},{"key":"6849_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1177\/1078155213510359","volume":"21","author":"BR Shank","year":"2015","unstructured":"Shank BR, Brown VT, Schwartz RN (2015) Multiple myeloma maintenance therapy: a review of the Pharmacologic treatment. J Oncol Pharm Pract 21:36\u201351. https:\/\/doi.org\/10.1177\/1078155213510359","journal-title":"J Oncol Pharm Pract"},{"key":"6849_CR23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.bbmt.2016.11.013","volume":"23","author":"D Sivaraj","year":"2017","unstructured":"Sivaraj D, Green MM, Li Z, Sung AD, Sarantopoulos S, Kang Y et al (2017) Outcomes of maintenance therapy with bortezomib after autologous stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transpl 23:262\u2013268. https:\/\/doi.org\/10.1016\/j.bbmt.2016.11.013","journal-title":"Biol Blood Marrow Transpl"},{"key":"6849_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00397-y","volume":"11","author":"MA Baertsch","year":"2021","unstructured":"Baertsch MA, Mai EK, Hielscher T, Bertsch U, Salwender HJ, Munder M et al (2021) Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma. Blood Cancer J 11:1. https:\/\/doi.org\/10.1038\/s41408-020-00397-y","journal-title":"Blood Cancer J"},{"key":"6849_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C et al (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:57\u201373. https:\/\/doi.org\/10.1016\/S1470-2045(18)30687-9","journal-title":"Lancet Oncol"},{"key":"6849_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M et al (2018) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood 131:301\u2013310. https:\/\/doi.org\/10.1182\/blood-2017-07-795047","journal-title":"Blood"},{"key":"6849_CR27","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R et al (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 28:5101\u20135109. https:\/\/doi.org\/10.1200\/JCO.2010.29.8216","journal-title":"J Clin Oncol"},{"key":"6849_CR28","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","volume":"116","author":"S Bringhen","year":"2010","unstructured":"Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R et al (2010) Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 116:4745\u20134753. https:\/\/doi.org\/10.1182\/blood-2010-07-294983","journal-title":"Blood"},{"key":"6849_CR29","doi-asserted-by":"publisher","first-page":"BSR20170304","DOI":"10.1042\/BSR20170304","volume":"37","author":"CY Sun","year":"2017","unstructured":"Sun CY, Li JY, Chu ZB, Zhang L, Chen L, Hu Y (2017) Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis. Biosci Rep 37:BSR20170304. https:\/\/doi.org\/10.1042\/BSR20170304","journal-title":"Biosci Rep"},{"key":"6849_CR30","doi-asserted-by":"publisher","first-page":"35","DOI":"10.21873\/cdp.10006","volume":"1","author":"Y Noguchi","year":"2021","unstructured":"Noguchi Y, Iriyama N, Takahashi H, Uchino Y, Nakagawa M, Hamada T et al (2021) Maintenance therapy with bortezomib and dexamethasone for Transplant-ineligible patients with multiple myeloma. Cancer Diagn Progn 1:35\u201342. https:\/\/doi.org\/10.21873\/cdp.10006","journal-title":"Cancer Diagn Progn"},{"key":"6849_CR31","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","volume":"4","author":"F Gay","year":"2018","unstructured":"Gay F, Jackson G, Rosi\u00f1ol L, Holstein SA, Moreau P, Spada S et al (2018) Maintenance treatment and survival in patients with myeloma: A systematic review and network Meta-analysis. JAMA Oncol 4:1389\u20131397. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2961","journal-title":"JAMA Oncol"},{"key":"6849_CR32","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","volume":"24","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos MA, Mikhael J, Terpos E, Leleu X, Moreau P, Blad\u00e9 J et al (2023) Management of multiple myeloma-related renal impairment: recommendations from the international myeloma working group. Lancet Oncol 24:e293\u2013311. https:\/\/doi.org\/10.1016\/S1470-2045(23)00223-1","journal-title":"Lancet Oncol"},{"key":"6849_CR33","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3324\/haematol.2015.133629","volume":"101","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastritis E et al (2016) Impact of renal impairment on outcomes with Lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 study in transplant-ineligible patients with multiple myeloma. Haematologica 101:363\u2013369. https:\/\/doi.org\/10.3324\/haematol.2015.133629","journal-title":"Haematologica"},{"key":"6849_CR34","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.20.01849","volume":"39","author":"KK Patel","year":"2021","unstructured":"Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF (2021) Cost-Effectiveness of First-Line versus Second-Line use of daratumumab in Older, Transplant-Ineligible patients with multiple myeloma. J Clin Oncol 39:1119\u20131128. https:\/\/doi.org\/10.1200\/JCO.20.01849","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06849-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06849-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:58:51Z","timestamp":1776405531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06849-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6849"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06849-w","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"2 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}